Cosmo Pharmaceuticals (OTC:CMOPF) Stock Price Up 20.5% – Here’s What Happened

Cosmo Pharmaceuticals (OTC:CMOPF)’s share price rose 20.5% during trading on Wednesday . The company traded as high as C$100.50 and last traded at C$98.58. Approximately 869 shares traded hands during mid-day trading, an increase of 143% from the average daily volume of 358 shares. The stock had previously closed at C$81.79.

Cosmo Pharmaceuticals Price Performance

The company has a 50-day simple moving average of C$82.80 and a two-hundred day simple moving average of C$75.17.

Cosmo Pharmaceuticals Company Profile

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.